Former Novartis AG Oncology CEO Liz Barrett will be the new CEO of the urology cancer specialist UroGen Pharma Ltd., the company announced Jan. 3, where she will be responsible for overseeing the FDA approval and launch of the company's first drug, now in late-stage development for low-grade upper tract urothelial cancer.
The news comes just about two weeks after Novartis announced Barrett's surprising departure after less than a year at the high-profile post. Novartis insider Susanne Schaffert, most recently the president of Novartis' newly acquired Advanced Accelerator Applications, was appointed to succeed her